Ceftolozane/tazobactam versus colistin in the treatment of ventilator-associated pneumonia due to extensively drug-resistant Pseudomonas aeruginosa.

Sci Rep · 2022 · PMC8924223 · PMID 35292686

Europe PMC DOI

hedged sentence

0.1800

closest p · 3.6× alpha

0.1800

boldest claim

The sentences

did not reach statistical significancep = 0.18not close (p > 0.1)

Treatment characteristics The median days of antibiotic therapy were longer in the CMS group (9 days, IQR 6–11 days), than for patients who received C/T (7 days, IQR 6–8 days), although the difference did not reach statistical significance (p = 0.18).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.